ERBB2 and breast carcinoma: Hurvitz et al. reported efficacy of neratinib plus capecitabine compared to lapatinib plus capecitabine in the subgroup of patients with central nervous system involvement from the NALA Trial on metastatic HER2 + breast cancer [34].